title: HER2 fragmentation and breast cancer stratification.
abstract: HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
authors.affiliation: Vall d'Hebron Institute of Oncology, Barcelona, Spain. jarribas@vhio.net
authors.forename: Joaquín
authors.initials: J
authors.lastname: Arribas
authors.forename: Josep Lluís
authors.initials: JL
authors.lastname: Parra-Palau
authors.forename: Kim
authors.initials: K
authors.lastname: Pedersen
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases